New Thresholds for AFP and Des-γ-Carboxy Prothrombin in Chronic Liver Disease Depending on the Use of Nucleoside Analogs and an Integrated Nomogram

References

• Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15(Suppl 4):5–13. doi:10.1634/theoncologist.2010-S4-05
   PubMed Web of Science ®Google Scholar
• Razavi-Shearer D, Gamkrelidze I, Nguyen MH, et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383–403. doi:10.1016/S2468-1253(18)30056-6
   PubMed Web of Science ®Google Scholar
• Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–538. doi:10.1016/j.jhep.2006.05.013
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ, Brown RJ, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology. 2016;63(1):284–306. doi:10.1002/hep.28280
   PubMed Web of Science ®Google Scholar
• Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98.
   PubMed Web of Science ®Google Scholar
• Lampertico P, Agarwal K, Berg T, et al. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. doi:10.1016/j.jhep.2017.03.021
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599.
   PubMed Web of Science ®Google Scholar
• Lim TS, Kim DY, Han KH, et al. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. Scand J Gastroenterol. 2016;51(3):344–353. doi:10.3109/00365521.2015.1082190
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–1022. doi:10.1002/hep.24199
   PubMed Web of Science ®Google Scholar
• Durazo FA, Blatt LM, Corey WG, et al. Des-γ-carboxyprothrombin, α-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroen Hepatol. 2008;23(10):1541–1548. doi:10.1111/j.1440-1746.2008.05395.x
   PubMed Web of Science ®Google Scholar
• Sultanik P, Ginguay A, Vandame J, et al. Diagnostic accuracy of des-gamma-carboxy prothrombin for hepatocellular carcinoma in a French cohort using the Lumipulse® G600 analyzer. J Viral Hepatitis. 2017;24(1):80–85. doi:10.1111/jvh.12622
   PubMed Web of Science ®Google Scholar
• Inagaki Y, Tang W, Makuuchi M, Hasegawa K, Sugawara Y, Kokudo N. Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-γ-carboxyprothrombin. Liver Int. 2011;31(1):22–35. doi:10.1111/j.1478-3231.2010.02348.x
   PubMed Web of Science ®Google Scholar
• Luo K, Liu Z, Karayiannis P. Effect of antiviral treatment on alfa-fetoprotein levels in HBV-related cirrhotic patients: early detection of hepatocellular carcinoma. J Viral Hepatitis. 2009. doi:10.1111/j.1365-2893.2009.01208.x
   PubMed Web of Science ®Google Scholar
• Kobashi H, Miyake Y, Ikeda F, et al. Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine. Hepatol Res. 2011;41(5):405–416. doi:10.1111/j.1872-034X.2011.00785.x
   PubMed Web of Science ®Google Scholar
• Yuen MF, Tanaka Y, Fong DY, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 2009;50(1):80–88. doi:10.1016/j.jhep.2008.07.023
   PubMed Web of Science ®Google Scholar
• Papatheodoridis G, Dalekos G, Sypsa V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol. 2016;64(4):800–806. doi:10.1016/j.jhep.2015.11.035
   PubMed Web of Science ®Google Scholar
• Yang H, Yuen M, Chan HL, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol. 2011;12(6):568–574. doi:10.1016/S1470-2045(11)70077-8
   PubMed Web of Science ®Google Scholar
• Jung KS, Kim SU, Song K, et al. Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy. Hepatology. 2015;62(6):1757–1766. doi:10.1002/hep.28115
   PubMed Web of Science ®Google Scholar
• Schotten C, Ostertag B, Sowa JP, et al. GALAD score detects early-stage hepatocellular carcinoma in a European cohort of chronic hepatitis B and C patients. Pharmaceuticals. 2021;14(8):735. doi:10.3390/ph14080735
   Web of Science ®Google Scholar
• Yang JD, Addissie BD, Mara KC, et al. GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score. Cancer Epidemiol Biomarkers Prev. 2019;28(3):531–538. doi:10.1158/1055-9965.EPI-18-0281
   PubMed Web of Science ®Google Scholar
• DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837–845. doi:10.2307/2531595
   PubMed Web of Science ®Google Scholar
• Zhou J, Sun H, Wang Z, et al. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer. 2020; 9(6):682–720
   Google Scholar
• Zhang J, Chen G, Zhang P, et al. The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One. 2020;15(2):e228857.
   Web of Science ®Google Scholar
• Li C, Zhang Z, Zhang P, Liu J. Diagnostic accuracy of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatocellular carcinoma: a systematic review. Hepatol Res. 2014;44(10):E11–E25. doi:10.1111/hepr.12201
   PubMed Web of Science ®Google Scholar
• Tateishi R, Yoshida H, Matsuyama Y, Mine N, Kondo Y, Omata M. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int. 2008;2(1):17–30. doi:10.1007/s12072-007-9038-x
   PubMed Web of Science ®Google Scholar
• Marrero JA, Feng Z, Wang Y, et al. α-fetoprotein, des-γ carboxyprothrombin, and lectin-bound α-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137(1):110–118. doi:10.1053/j.gastro.2009.04.005
   PubMed Web of Science ®Google Scholar
• Zhang C, Chen X, Liu H, et al. Alpha fetoprotein mediates HBx induced carcinogenesis in the hepatocyte cytoplasm. Int J Cancer. 2015;137(8):1818–1829. doi:10.1002/ijc.29548
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Imamura H, Matsuyama Y, et al. Significance of alpha-fetoprotein and des-γ-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol. 2009;16(10):2795–2804. doi:10.1245/s10434-009-0618-y
   PubMed Web of Science ®Google Scholar
• Yu R, Ding S, Tan W, et al. Performance of protein induced by vitamin K absence or antagonist-II (PIVKA-II) for hepatocellular carcinoma screening in Chinese population. Hepat Mon. 2015;15(7). doi:10.5812/hepatmon.28806v2.
   PubMed Web of Science ®Google Scholar
• Ji J, Wang H, Li Y, et al. Diagnostic evaluation of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatitis B virus-related hepatocellular carcinoma in china: a large-scale, multicentre study. PLoS One. 2016;11(4):e153227. doi:10.1371/journal.pone.0153227
   Web of Science ®Google Scholar
• Chan SL, Mo F, Johnson PJ, et al. Performance of serum α-fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass. HPB. 2014;16(4):366–372. doi:10.1111/hpb.12146
   PubMed Web of Science ®Google Scholar
• Trevisani F, D’Intino PE, Morselli-Labate AM, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001;34(4):570–575. doi:10.1016/S0168-8278(00)00053-2
   PubMed Web of Science ®Google Scholar
• Zhang L, Wu GY, Wu YJ, Liu SY. The serum metabolic profiles of different Barcelona stages hepatocellular carcinoma associated with hepatitis B virus. Oncol Lett. 2018;15(1):956–962.
   PubMed Web of Science ®Google Scholar
• Liu C, Xiao GQ, Yan LN, et al. Value of alpha-fetoprotein in association with clinicopathological features of hepatocellular carcinoma. World J Gastroenterol. 2013;19(11):1811–1819. doi:10.3748/wjg.v19.i11.1811
   PubMed Web of Science ®Google Scholar
• Yuan G, Zhou Y, Liu J, et al. AFP specificity for HCC surveillance is increased by mitigating liver injury among treated chronic hepatitis B patients with elevated AFP. Int J Clin Exp Pathol. 2019;12(4):1315–1323.
   PubMed Web of Science ®Google Scholar
• Wang L, Huang J, Jiang M, Zheng X. AFP computational secreted network construction and analysis between human hepatocellular carcinoma (HCC) and no-tumor hepatitis/cirrhotic liver tissues. Tumour Biol. 2010;31(5):417–425. doi:10.1007/s13277-010-0050-8
   PubMedGoogle Scholar
• Notarpaolo A, Layese R, Magistri P, et al. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. J Hepatol. 2017;66(3):552–559. doi:10.1016/j.jhep.2016.10.038
   PubMed Web of Science ®Google Scholar
• Cai D, Pan C, Yu W, et al. Comparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive HBeAg-positive patients with chronic hepatitis B: a large, multicentre, randomized controlled trials. Medicine. 2019;98(1):e13983. doi:10.1097/MD.0000000000013983
   PubMed Web of Science ®Google Scholar
• Zhang JY, Song CH, Shi F, Zhang Z, Fu JL, Wang FS. Decreased ratio of Treg cells to Th17 cells correlates with HBV DNA suppression in chronic hepatitis B patients undergoing entecavir treatment. PLoS One. 2010;5(11):e13869. doi:10.1371/journal.pone.0013869
   PubMed Web of Science ®Google Scholar
• Chang TT, Lai CL, Kew YS, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51(2):422–430. doi:10.1002/hep.23327
   PubMed Web of Science ®Google Scholar
• Tseng CH, Tseng CM, Wu JL, Hsu YC, El-Serag HB. Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: a systematic review. J Gastroen Hepatol. 2020;35:1684–1693. doi:10.1111/jgh.15078
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Pirrie SJ, Cox TF, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidem Biomar. 2014;23(1):144–153. doi:10.1158/1055-9965.EPI-13-0870
   PubMed Web of Science ®Google Scholar
• Berhane S, Toyoda H, Tada T, et al. Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. Clin Gastroenterol Hepatol. 2016;14(6):875–886.
   PubMed Web of Science ®Google Scholar
• Liu M, Wu R, Liu X, et al. Validation of the GALAD model and establishment of GAAP model for diagnosis of hepatocellular carcinoma in Chinese patients. J Hepatocell Carcinoma. 2020;7:219–232. doi:10.2147/JHC.S271790
   PubMed Web of Science ®Google Scholar
• Lou T, Li B, Xiong P, Jin C, Chen Y. External validation of hepatocellular carcinoma risk scores in patients with chronic hepatitis B virus infection in China. J Viral Hepat. 2021. doi:10.1111/jvh.13569
   PubMed Web of Science ®Google Scholar
• Wu T, Li J, Shao L, et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. GUT. 2018;67(12):2181–2191. doi:10.1136/gutjnl-2017-314641
   PubMed Web of Science ®Google Scholar
• Liu H, Zhang H, Wan G, et al. Neutrophil-lymphocyte ratio: a novel predictor for short-term prognosis in acute-on-chronic hepatitis B liver failure. J Viral Hepatitis. 2014;21(7):499–507. doi:10.1111/jvh.12160
   PubMed Web of Science ®Google Scholar
• Wong GL, Chan HL, Tse YK, et al. On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. Hepatology. 2014;59(3):986–995. doi:10.1002/hep.26739
   PubMed Web of Science ®Google Scholar
• Kim GA, Seock CH, Park JW, et al. Reappraisal of serum alpha-foetoprotein as a surveillance test for hepatocellular carcinoma during entecavir treatment. Liver Int. 2015;35(1):232–239. doi:10.1111/liv.12516
   PubMed Web of Science ®Google Scholar